We aimed to evaluate real‐world glycaemic outcomes of a tubeless hybrid closed‐loop (HCL) insulin delivery system in type 1 diabetes (T1D), exploring the influence of ethnicity and socioeconomic status from a publicly funded system with universal access. Here, INS is linked to type 1 diabetes mellitus.